Global Liver Institute

News

GLOBAL LIVER INSTITUTE

News
Tackling Fatty Liver Disease

Tackling Fatty Liver Disease

As the field of NASH is on the verge of clinical and diagnostic breakthroughs, discover how GLI is promoting healthier living through our personalized nutrition solution, advocating for greater inclusion in clinical trials, and recognizing the role of drug safety and efficacy.

read more
GLI Supports NIH Naming Dr. Marrazzo as New Director of the National Institute of Allergy and Infectious Diseases

GLI Supports NIH Naming Dr. Marrazzo as New Director of the National Institute of Allergy and Infectious Diseases

Global Liver Institute supports the selection of Jeanne M. Marrazzo, M.D., as director of the National Institute of Allergy and Infectious Diseases (NIAID) by the acting director of the NIH. Dr. Marrazzo is currently the director of the Division of Infectious Diseases at the University of Alabama at Birmingham and is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America.

read more
Technology at Work

Technology at Work

Read along for some updates about cutting-edge technology in rare liver disease that should improve prompt diagnosis, ongoing feedback, and effective interventions.

read more
GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)

GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)

Global Liver Institute recognizes the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH affects more than 148 million people and continues to become more prevalent each year.

read more